The present invention relates to the use of compounds for the treatment of angiogenesis related disorders involving a protein kinase as a medicament. The compounds e.g. have the general formula I. In preferred embodiments Rl and R5 are independently selected from hydrogen, halogen, cyano, nitro, CF3 and methyl, R2 and R4 are independently selected from hydrogen, alkyl and NHR7, wherein R7 is optionally substituted aryl, and R3 is optionally substituted C1-C6 alkyl, optionally substituted aryl or optionally substituted 5-or 6-membered heterocycle.